FAQ-4 19- What Chances for Stem Cell Success When I Get Stem Cell Therapy? youtu.be Whether as differentiated or undifferentiated, whether from sheep stem cells or from rabbit stem cells; delivered frozen or fresh, today's stem cell therapies are showing real promise and helping HIV-AIDS sufferers around the world, today! Cautious not to claim they can cure ANYTHING, today's ethical clinics offer hope for AIDS-HIV sufferers worldwide, although the one Thai clinic licensed by the German stem cell technique is in Bangkok. For information to help you make an informed, personal decision, check out StemCell-Asia.info today.From:VeteransRecallViews:0 0ratingsTime:01:38More inPeople Blogs Read more from the original source: FAQ-4 19- What Chances for Stem Cell Success When I Get Stem Cell Therapy? - Video … Continue reading →

[RMS] C-Class Stem Cell Processing Center (SPC) C-Type Member practice stem cell therapy with setting up C-class Stem cell Processing Center. Single platform with necessary equipments (including the ones for quality control tests) built in single space for the production of Chondron processing room, preparation room, utility room.From:SewonCellontechViews:0 0ratingsTime:00:46More inHowto Style Go here to read the rest: [RMS] C-Class Stem Cell Processing Center (SPC) - Video … Continue reading →

By Philip C. Tubeza Philippine Daily Inquirer Stem cell therapy might provide a remedy for acquired immunodeficiency syndrome (AIDS) after it was used on an HIV patient in Germany, the first person known to have been cured of the disease, a Department of Health (DOH) official said Tuesday. Dr. Gerald Belimac, program manager of the DOH National AIDS/Sexually Transmitted Infection Prevention and Control Program, said American Timothy R. Brown, the so-called Berlin Patient who had been infected with the human immunodeficiency virus, was cured after getting stem cells in 2007 from a donor who was genetically resistant to the virus that caused AIDS. However, he said that this procedure was very complex and was still under study. It takes the right person, the right recipient, the right donor, for a stem cell transplantation particularly on HIV to be successful, Belimac said. If it comes from other donors, there is really a high chance that the recipient would reject it, she added. Brown was infected with HIV in 1995 and was later diagnosed with leukemia, or cancer of the blood. He underwent a transplant of stem cells for the leukemia and it turned out that those stem cells had genes that … Continue reading →

MANILA, Philippines Amid the recent warning issued by the Department of Health (DOH) regarding stem cell therapy, doctors who are offering the treatment in the Philippines clarified that they are not promising a cure. We are very careful about claiming cure. These days ang dami nagsasalita, nawala ang sakit. All of a sudden siya (stem cell therapy) na yung magic bullet ng buong mundo, like if you get stem cell, you get cured, said Dr. Michelle de Vera, deputy director of the Institute of Personalized Molecular Medicine at The Medical City. Kapag may narinig na ganyan dapat lalo silang mag-ingat. Cure is zero evidence of disease or kung genetic yung disease dapat napalitan yung genes mo. Hindi mangyayari yun at this point," he stressed. De Vera, an allergologist and immunologist, does stem cell therapy on her patients at The Medical City but he said he believes that the DOH is right in warning patients on stem cell therapy. Tama naman na magbigay sila ng warning,I think what their trying to do is regulate stem cell therapy, the doctor said. Public advisory The DOH recently came out with a public advisory on stem cell therapies saying that there is an "observed … Continue reading →

By Erika Sauler Philippine Daily Inquirer MANILA, Philippines This type of stem cell therapy does not claim to be the fountain of youth, but an alternative treatment to arthritis, muscle pain and tendon tear. Two Filipino doctors who trained in the United States said in a media forum on Sunday that autologous stem cell therapy could speed up the healing of musculoskeletal and sports-related injuries, which could be an optional remedy before undergoing surgery. Dr. Jeimylo de Castro explained that the procedure would involve taking stem cells from the patients blood, fat tissue or bone marrow and injecting them to the injured area of the same person. This type of therapy is different from the controversial embryonic stem cells which are harvested from animals or fertilized eggs. With stem cell therapy being a current fad for anti-aging, the Department of Health has warned the public that the benefits of stem cell therapy are still under evaluation. The DOH will soon issue guidelines for the use of stem cell therapy and the licensing of facilities offering this service. De Castro and Dr. Franklin Domingo are both fellows of the Philippine Academy of Rehabilitation Medicine. They underwent training for stem cell therapy … Continue reading →

Multiple Sclerosis If you believe that there may be new and important information related to treatment with mesenchymal stem cells of multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), we are pleased to advise you to look at the filmstrip on the right and read more information on this website, about Professor Slavin, a world-renowned expert on the treatment of these diseases, offered in private clinics run by him, in Israel. Dr. Shimon Slavin of the International Center for Cell Therapy and Cancer Immunotherapy in Tel Aviv, told CTV News: "Early data from more than 100 patients treated thus far suggests that mesenchymal stem cell treatment can repair existing damage to the nervous system in a significant number of patients in need."From:diegofridmanViews:93 0ratingsTime:02:05More inScience Technology Read the original post: Multiple Sclerosis - Video … Continue reading →

ST. LOUIS, Oct. 25, 2012 (GLOBE NEWSWIRE) -- ISTO Technologies, Inc. announced today that it has received the 2012 Spine Technology Award for its NuQu(R) technology. This award, which is announced annually by Orthopedics This Week and RRY Publications, is to be presented this week at the North American Spine Society annual meeting in Dallas, Texas. The purpose of the award is to honor the best products, engineering teams, and inventors in spine surgery. ISTO received this award for its scientific innovation in the category of Biomaterials and Biologics. NuQu is comprised of tissue expanded juvenile chondrocytes, and is under clinical investigation for the treatment of pain and disability associated with lumbar degenerative disc disease. Currently there is no available treatment for patients who fail traditional conservative management of discogenic back pain. NuQu may represent a break though treatment which promotes healing of the disc and allows a cost effective non-surgical solution to chronic disability. ISTO announced on October 22nd 2012 that it is initiating a Phase II trial to further evaluate the efficacy and safety of its NuQu cell-based therapy for the treatment of pain and disability associated with degenerated spinal discs. The company expects to commence enrollment in … Continue reading →

PARIS--(BUSINESS WIRE)-- The C4C consortium today announced the implementation of France's first ever dedicated technical facility for the manufacture of cell therapy products. The C4C project (coordinated by CELLforCURE, a subsidiary of the leading French biopharmaceutical company LFB Biotechnologies) brings together the skills of two biotech companies (Celogos and CleanCells) and seven public-sector organizations and university medical centers (the French Blood Agency's [Etablissement Franais du Sang, EFS] directorates in the Aquitaine-Limousin and Pyrnes-Mditerrane regions of France, Bordeaux University Medical Center [CHU de Bordeaux], Lille University Medical Center/University of Lille 2 [CHU de Lille], Nantes University Medical Center, [CHU de Nantes] and the Biological Resource Center at Lyons University Medical Center [Banque de Tissus et de Cellules des Hospices Civils de Lyon]. The first five products are currently being developed, with a view to validating the facility dedicated to the routine production of clinical trial and therapeutic batches. This facility is located on LFB's site in Les Ulis, close to Paris. C4C is an ambitious project that has attracted 80 million euros in investment from the consortium members and 30 million euros in public-sector financial aid (provided by OSEO, France's state innovation agency). In fact, C4C was selected by OSEO as … Continue reading →

Public release date: 22-Oct-2012 [ | E-mail | Share ] Contact: Yivsam Azgad news@weizmann.ac.il 972-893-43856 Weizmann Institute of Science Hiding deep inside the bone marrow are special cells. They wait patiently for the hour of need, at which point these blood forming stem cells can proliferate and differentiate into billions of mature blood immune cells to help the body cope with infection, for example, or extra red blood cells for low oxygen levels at high altitudes. Even in emergencies, however, the body keeps to a long-term plan: It maintains a reserve of undifferentiated stem cells for future needs and crises. A research team headed by Prof. Tsvee Lapidot of the Institute's immunology Department recently discovered a new type of bodyguard that protects stem cells from over-differentiation. In a paper that appeared in Nature Immunology, they revealed how this rare, previously unknown sub-group of activated immune cells keeps the stem cells in the bone marrow "forever young." Blood forming stem cells live in comfort in the bone marrow, surrounded by an entourage of support cells that cater to their needs and direct their development the mesenchymal cells. But the research team, which included postdoctoral fellow Dr. Aya Ludin, Prof. Steffen Jung … Continue reading →

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR) today announced that it will report its financial results for the third quarter ended September 30, 2012, on Monday, November 5, 2012. C. Randal Mills, Ph.D., President and Chief Executive Officer, and Philip R. Jacoby, Jr., Chief Financial Officer, will provide a company update and discuss results via a webcast and conference call on Monday, November 5, 2012 at 9:00 a.m. ET. To access the webcast, visit the Investor Relations section of the company's website at http://investor.osiris.com/events.cfm. Alternatively, callers may participate in the conference call by dialing (877) 303-6133 (U.S. participants) or (970) 315-0493 (international participants). An archive of the webcast will be available approximately two hours after the completion of the call through November 12, 2012. To access the archived webcast, visit the Investor Relations section of the company's website at http://investor.osiris.com/events.cfm. About Osiris Therapeutics Osiris Therapeutics, Inc. is the leading stem cell company, having developed the worlds first approved stem cell drug, Prochymal. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets. In Biosurgery, Osiris currently markets Grafix for burns and chronic wounds, and Ovation for orthopedic applications. Osiris … Continue reading →